Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
8
Polynovo Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
stocks
The ASX’s most shorted stocks
stocks
Will CEO departure upend ASX healthcare leader?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,061.20 | 61.30 | -0.67% |
CAC 40 | 7,853.59 | 1.02 | -0.01% |
DAX 40 | 23,639.41 | 35.12 | -0.15% |
Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
FTSE 100 | 9,216.67 | 11.44 | -0.12% |
HKSE | 26,545.10 | 106.59 | 0.40% |
NASDAQ | 22,631.48 | 160.75 | 0.72% |
Nikkei 225 | 45,045.81 | 143.54 | 0.32% |
NZX 50 Index | 13,231.66 | 3.23 | -0.02% |
S&P 500 | 6,664.36 | 32.40 | 0.49% |
S&P/ASX 200 | 8,773.50 | 75.00 | -0.85% |
SSE Composite Index | 3,820.09 | 11.57 | -0.30% |